In many instances, particularly during hyponatremia and hypernatremia, plasma sodium likely contributes to the control of blood pressure. As is clear when considering the action of diuretics that suppress tubular sodium reabsorption, plasma sodium, and thus blood pressure, is influenced by renal sodium excretion. Renal sodium excretion is fine-tuned in the aldosterone-sensitive distal nephron (ASDN). The epithelial Na^+^ channel (ENaC) is expressed in the apical plasma membrane of principal cells of the ASDN (Garty and Palmer, [@B14]; Kellenberger and Schild, [@B21]). Here, ENaC serves as the primary cell entry pathway for electrogenic Na^+^ reabsorption from the urine back into interstitial fluid. Consequently, the activity of ENaC is limiting for trans-cellular sodium reabsorption across the ASDN.

Normal ENaC function is required for proper sodium balance and thus, normal blood pressure. Gain-of-function mutations in ENaC cause inappropriate renal sodium retention and consequent increases in mean arterial pressure (Lifton et al., [@B24]; Rossier et al., [@B32]). Inhibition of ENaC corrects the renal and blood pressure phenotypes resulting from such mutations. Loss-of-function mutations in ENaC, in contrast, cause renal sodium wasting and corresponding decreases in blood pressure (Rossier et al., [@B32]; Geller, [@B15]).

As a key end-effector modulating blood pressure, the activity of ENaC in the ASDN, as depicted in (the right of) Figure [1](#F1){ref-type="fig"} is under negative-feedback regulation by the renin-angiotensin-aldosterone system (RAAS). The mineralocorticoid, aldosterone, is the final hormone in this cascade. This anti-natriuretic factor is essential for proper Na^+^ balance (Horisberger and Diezi, [@B19]). Decreases in blood pressure evoke via renin-AngII signaling secretion of aldosterone from the adrenal gland. Aldosterone through the mineralocorticoid receptor (MR) stimulates ENaC in the ASDN to minimize renal sodium excretion in protection of plasma sodium (Rossier et al., [@B32]; Geller, [@B15]). Pathological increases in aldosterone elevate blood pressure by promoting inappropriate renal sodium retention (White, [@B38]; Gomez-Sanchez, [@B16]). Inhibition of ENaC ameliorates this. In contrast, pathological decreases in aldosterone result in sodium wasting arising from inappropriate increases in renal sodium excretion (White, [@B38]; Geller, [@B15]). MR agonism and antagonism increase and decrease ENaC activity, respectively (Kemendy et al., [@B22]; Pácha et al., [@B29]; Palmer et al., [@B28]). Simply put, there is strong support for a tight positive relation between the levels and actions of aldosterone and ENaC activity, renal sodium reabsorption and blood pressure. In this sense, activation of ENaC is anti-natriuretic protecting plasma sodium and blood pressure.

![**Regulation of ENaC by aldosterone and vasopressin**. Vasopressin release is stimulated primarily by increases in plasma osmolality but also by decreases in mean arterial pressure and is also under feedback control by the hypothalamic-pituitary-adrenal (HPA) axis as mediated by glucocorticoids. Positive and negative relations are indicated by blue and red, respectively. Weaker regulation indicated with narrower arrows.](fphys-03-00304-g0001){#F1}

Because of the abundance of seminal discoveries establishing this strong causal relation between changes in aldosterone, ENaC activity and blood pressure, the role of ENaC in health and disease is understood almost exclusively through the concept of feedback regulation by the RAAS (Garty and Palmer, [@B14]; Lifton et al., [@B24]; Rossier et al., [@B32]; Geller, [@B15]). Emerging evidence, though, argues that this dogma is inadequate too narrowly defining the role of ENaC in sodium and water balance. For instance, ENaC activity is high, in some instances, in the absence of significant changes in aldosterone (Palmer et al., [@B28]; Mironova et al., [@B27]). This form of regulation is termed aldosterone-independent in the current review. Several hormones in addition to aldosterone modulate the activity of ENaC. Vasopressin (AVP) decreases renal sodium excretion by increasing the activity of ENaC and sodium reabsorption in the ASDN in parallel with aldosterone (Bankir, [@B3]; Perucca et al., [@B30]; Stockand, [@B34]; Blanchard et al., [@B6]). Indeed, both AVP and aldosterone are required to achieve maximal urinary concentration: minimization of free water excretion.

The antidiuretic hormone, AVP, increases free water reabsorption by stimulating aquaporin 2 water channels in the distal nephron (Bankir, [@B3]; Fenton and Knepper, [@B9]). The axial corticomedullary hyperosmotic gradient as established by the loop of Henle provides the draw for this AQP2-mediated water reabsorption. In addition to being anti-aquaretic, AVP is anti-natriuretic (Helman et al., [@B18]; Frindt and Burg, [@B13]; Andersen et al., [@B2]; Bankir et al., [@B4]). As extrapolated from rich but indirect evidence, ENaC, as shown in (the left of) Figure [1](#F1){ref-type="fig"}, appears to be a target for AVP in this regard. AVP stimulates sodium reabsorption in isolated perfused ASDN in an amiloride-sensitive manner, and amiloride inhibits the anti-natriuretic actions of AVP in man (Helman et al., [@B18]; Frindt and Burg, [@B13]; Reif et al., [@B31]; Tomita et al., [@B36]; Schlatter and Schafer, [@B33]; Hawk et al., [@B17]). Amiloride is a blocker of ENaC. Moreover, V~2~ receptor antagonism promotes sodium excretion in addition to water excretion (Andersen et al., [@B2]; Bankir, [@B3]; Bankir et al., [@B4]; Perucca et al., [@B30]). The V~2~ receptor mediates AVP actions in the ASDN (see Stockand, [@B34] for a recent review of AVP signaling and actions on ENaC in the ASDN). AVP also increases the trans-epithelial voltage difference across isolated ASDN consistent with it activating electrogenic transport processes (Helman et al., [@B18]; Frindt and Burg, [@B13]; Reif et al., [@B31]; Schlatter and Schafer, [@B33]; Hawk et al., [@B17]). Cell entry of sodium across the apical membrane via ENaC, as discussed above, is the limiting step in electrogenic sodium reabsorption in the ASDN. Moreover, AVP increases the activity of ENaC in cultured immortalized renal cells (Marunaka and Eaton, [@B26]). Recently, we demonstrated that AVP increases the activity of ENaC in freshly isolated, split-open murine ASDN (Bugaj et al., [@B7]).

As discussed above, regulation of plasma sodium and thus, volume is considered to be under the purview of the RAAS with ENaC playing a critical role in this process; and plasma osmolality under the control of feedback regulation by AVP with AQP2 being the critical end-effector in this process. However, the compelling support for AVP-activation of ENaC suggests that these paradigms need to be broadened to incorporate the concept that activation of ENaC in the presence of activated AQP2 contributes to the draw for water reabsorption out of the ASDN. This would be consistent with the function of ENaC (in the presence of activated AQP2) being shifted by AVP from protecting plasma sodium to facilitating water reabsorption. This exciting idea raises several questions centered on the hypothesis that the function of ENaC in the ASDN (with respect to systemic sodium and water balance) dependents on whether the channel is activated in the absence or presence of simultaneous activation of AQP2 water channels where AVP activates both ENaC and AQP2.

Upon initial consideration, the idea that AVP-activated ENaC facilitates free water reabsorption seems counter-intuitive to the established role for this channel in protecting plasma sodium. However, the essential question here is whether ENaC activated in the ASDN in the presence of AQP2 contributes more to the draw for free water reabsorption or plasma \[Na^+^\]: a question that largely remains to be answered. Insight, though, can be gleamed from several recent findings as discussed below.

Addressing whether ENaC activated in the presence of active AQP2 by AVP influences the draw for free water more than plasma \[Na^+^\] is significant for it will define the paradigm (refer to Table [1](#T1){ref-type="table"}) by which we understand the role of ENaC in hyponatremic and hypernatremic states of low aldosterone but high AVP. Elaboration of this question, moreover, is significant because it also will define the limitations of having two distinct feedback systems, one responsive to and controlling plasma \[Na^+^\]/volume and the other plasma osmolality/water content, competing using a common final effector, ENaC (refer to Table [1](#T1){ref-type="table"}).

###### 

**The consequences of active ENaC in states of high AVP and low aldosterone**.

  **State**   **AVP**   **Aldo**   **ENaC activity**   **Volume**   **P~Na~**   **Potential role of ENaC decreasing excretion of[^a^](#TN1){ref-type="table-fn"}**   
  ----------- --------- ---------- ------------------- ------------ ----------- ------------------------------------------------------------------------------------ ------------------------
  Adx         ↑         ↓          Robust              ↓            ↓           Compensatory to volume                                                               Causal to hyponatremia
  SIADH       ↑         ↓          ?                   --           ↓           Compensatory to hyponatremia                                                         Causal to hyponatremia

The role of ENaC will depend on whether it has a relatively greater effect on decreasing renal sodium excretion vs. free water excretion.

Aldosterone signaling through MR is sufficient but is it necessary for ENaC activity?
=====================================================================================

All studies investigating the actions of aldosterone on (amiloride-sensitive) renal sodium excretion, transport and the activity of ENaC in the ASDN are in agreement that increases in aldosterone are sufficient to increase ENaC activity (Pácha et al., [@B29]; Palmer et al., [@B28]). Decreased amiloride-sensitive sodium excretion resulting from gain-of-function mutations in MR and increases in aldosterone signaling also are in agreement on this point (White, [@B38]; Gomez-Sanchez, [@B16]; Geller, [@B15]).

The strong inverse relation between sodium intake and aldosterone levels and ENaC activity are consistent with aldosterone being necessary for the activity of this channel. In agreement are findings that MR antagonism decrease ENaC activity and increase renal sodium excretion (Pácha et al., [@B29]; Palmer et al., [@B28]). Moreover, recent results form genetically modified mice lacking MR or aldosterone synthase (AS) also support this position. MR null mice do not survive long after the first week of life without sodium supplementation due to pathological renal sodium excretion (Berger et al., [@B5]). Similarly, AS null mice have pronounced renal sodium and water wasting (Lee et al., [@B23]; Makhanova et al., [@B25]). Sodium restriction exacerbates renal salt and water wasting in both AS and MR null mice as compared to control animals, which have appropriate feedback regulation of ENaC by RAAS. These observations are reminiscent of human infants carrying inactivating MR mutations and AS deficiency, which require sodium supplementation to survive (White, [@B38], [@B39]; Geller, [@B15]).

However, this issue is more complex than the above findings would seem to suggest. It was demonstrated recently that the inverse relation between sodium intake and ENaC activity is not solely dependent on aldosterone signaling (Toney et al., [@B37]), and neonatal MR null mice retain residual but significant ENaC activity, approximately 24% of normal, as extrapolated from amiloride-sensitive fractional Na^+^ excretion and transport across isolated, perfused collecting ducts (Berger et al., [@B5]). Such results are not consistent with aldosterone being an absolute requirement for ENaC activity in the ASDN. The strongest support for this, though, comes from recent findings that ENaC is expressed and active in the absence of aldosterone in adrenalectomized mice (Mironova et al., [@B27]). Thus, there are some instances where ENaC is active in the absence of aldosterone signaling. These exceptions then demonstrate that aldosterone is not necessary for the activity of ENaC in the ASDN. This raises the questions of what is maintaining ENaC activity high in the absence of aldosterone in these circumstances and what are the consequences of aldosterone-independent activation of ENaC.

Aldosterone-independent activation of ENaC by AVP in hyponatremic states
========================================================================

The first clue to answering these questions comes from understanding that the hormonal state and thus phenotype of loss-of-function of MR or AS does not completely overlap that of adrenalectomy. With MR dysfunction, the RAAS is up-regulated (Berger et al., [@B5]). With AS dysfunction, aldosterone is absent but the levels of other adrenal steroids capable of mineralocorticoid action, in particular corticosterone, are increased (White, [@B39]; Lee et al., [@B23]). With adrenalectomy, there is no aldosterone or other adrenal steroids and catecholamines and thus, these animals receive no input from the adrenal gland to ENaC. Moreover, akin to adrenal insufficiency, removal of the adrenal glands causes marked increases in plasma AVP levels (Friedman et al., [@B12]; Ahmed et al., [@B1]; Ishikawa and Schrier, [@B20]). This is not present with either MR or AS dysfunction (Makhanova et al., [@B25]).

Usually, AVP release is primarily controlled by plasma osmolality. Elevated AVP release in adrenal insufficient states (that lack both glucocorticoids and mineralocorticoids) results form two events. There is loss of negative-feedback regulation by glucocorticoids of the hypothalamic-pituitary axis controlling AVP release and there is strong non-osmotic stimulation of AVP release resulting from volume depletion due to sodium and water wasting by the kidney (Ahmed et al., [@B1]; Ishikawa and Schrier, [@B20]).

The second clue comes from recognizing that adrenal insufficiency and central diabetes insipidus are counterpoints when considering the equilibrium distribution of sodium and water: the pattern of sodium and water distribution in either deficiency depends in part on the activity of the remaining gland. As such, the hyponatremia of adrenal insufficiency is absent when combined with neurohypophyseal deficiency and in the Brattleboro rat, which has central diabetes insipidus (Friedman et al., [@B11],[@B12]; Foy and Schnieden, [@B10]; Ahmed et al., [@B1]). Thus, the hyponatremia of adrenal insufficiency is dependent on elevated AVP release.

As discussed above, AVP is known to decrease renal Na^+^ excretion by increasing reabsorption in the ASDN by stimulating ENaC activity. Akin to its regulation of AQP2 water channels, AVP stimulates ENaC in principal cells via the V~2~ receptor (Bugaj et al., [@B7]; Stockand, [@B34]). Inhibition of the V~2~ receptor decreases ENaC activity in the ASDN of adrenaletomized mice to levels that are identical to those observed in control animals (Mironova et al., [@B27]). This demonstrates that elevated AVP is the driving force maintaining ENaC activity high in the absence of aldosterone in adrenalectomized mice. Could this aldosterone-independent AVP-stimulation of ENaC (in the presence of activated AQP2) be contributing to the draw of water out of the collecting duct and thus, be contributing to the hyponatremia common to adrenal insufficiency? As depicted in Table [1](#T1){ref-type="table"} only additional research will clarify this issue.

To appreciate the potential consequences of aldosterone-independent activation of ENaC by AVP, it must be recognized that with adrenalectomy ENaC is no longer regulated in a normal manner by feedback signaling in response to changes in sodium balance. This is a result of stimulation by elevated AVP release combined with disruption of regulation by the RAAS. Rather in adrenal insufficient states, ENaC is regulated primarily by AVP: a hormone that normal controls plasma osmolality.

Adrenalectomy, similar to other adrenal insufficient states, though, causes pronounced renal sodium and volume wasting; likely through loss of a non-ENaC, aldosterone-dependent but AVP-insensitive mechanism (Mironova et al., [@B27]). This muddies the waters with respect to whether AVP-dependent stimulation of ENaC in adrenal insufficiency is a compensatory response to decreases in volume or a result independent of actions on vascular volume. It is noteworthy that AS and MR null mice also have significant renal salt and water and thus, volume loss but the activity of ENaC under these conditions, which are not noted for significant increases in \[AVP\], is markedly less than that in adrenalectomized mice, which do have elevated \[AVP\]. Regardless of whether increases in ENaC activity are compensatory or not, a consequence of adrenal insufficiency is that AVP-stimulated ENaC, in the absence of input from RAAS, becomes a slave to water reabsorption rather than a key mediator of sodium balance possibly exacerbating the hyponatremia of this state. As outlined in Table [1](#T1){ref-type="table"}, a definitive test of the role of AVP-activated ENaC during adrenal insufficiency will be to determine whether blockade of this channel betters or worsens the hyponatremia of this state. As yet these experiments have not been performed.

Unlike adrenal insufficiency, hyponatremia in the syndrome of inappropriate ADH (AVP) secretion (SIADH) is not associated with hypovolemia. No results are available currently regarding ENaC activity in this condition and thus, it is unclear if increases in AVP in this setting also stimulate ENaC. Prolonged agonism of the V~2~ receptor in a rat model of SIADH, though, increased ENaC abundance even in the absence of input from the adrenal gland (Ecelbarger et al., [@B8]; Tiwari et al., [@B35]). Unfortunately, no information exists currently regarding whether inhibition of ENaC betters or worsens hyponatremia in SIADH. Such studies are key for they will elaborate the effects of AVP-dependent stimulation of ENaC in hyponatremic states with and without confounding hypovolemia.

Concluding remarks
==================

While several key questions remain about the physiological and pathological consequences of AVP-stimulation of ENaC, it is clear that AVP can increase the activity of this channel. This positions ENaC to be an end-effector of both aldosterone, as the final signal in the RAAS and AVP. Signaling through RAAS, in part because it activates ENaC, influences plasma sodium and thus, blood pressure; and signaling by AVP influences free water reabsorption, in part, because it activates AQP2. As argued above, AVP-stimulated ENaC likely facilitates water reabsorption. This contributes to protection of vascular volume as likely is the case in adrenal insufficiency, but does it do so at the expense of facilitating hyponatremia? Such a question highlights the potential limitations imposed by the mechanics of water movement only through osmosis in biological systems and by the evolution of the mammalian renal tubule where ENaC sits at the intersection of two homeostatic control systems one responding to and influencing plasma sodium, and the other plasma osmolality that must by their nature sometimes be in competition.
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